GEHCHealthcare · Medical DevicesThe 21 Wall Street analysts covering GE Healthcare Technologies, Inc. hold a median 12-month price target of $84 — +22.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 14 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores GE Healthcare Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (37): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GEHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | BTIG | Maintains | Buy | $79 → $75 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $85 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $75 → $71 |
| 5 Oct 2026 | Needham | Reiterates | Buy | $93 |
| 22 Sept 2026 | Needham | Initiates | Buy | — |
| 22 Sept 2026 | Needham | Initiates | Buy | $93 |
| 17 Sept 2026 | BTIG | Reiterates | Buy | $79 |
| 17 Sept 2026 | BTIG | Reiterates | Buy | — |
| 19 Aug 2026 | BTIG | Reiterates | Buy | $79 |
| 19 Aug 2026 | BTIG | Reiterates | Buy | — |
| 31 July 2026 | UBS | Maintains | Neutral | — |
| 31 July 2026 | UBS | Maintains | Neutral | $67 → $73 |
| 30 July 2026 | Citigroup | Maintains | Neutral | — |
| 30 July 2026 | Citigroup | Maintains | Neutral | $69 → $75 |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 30 July 2026 | Evercore ISI Group | Maintains | Outperform | $80 → $84 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $75 → $85 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 29 July 2026 | BTIG | Maintains | Buy | $75 → $79 |
| 29 July 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GEHC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, GE Healthcare Technologies, Inc. returned −5.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 59% of US stocks
Cheaper than 32% of US stocks
Cheaper than 33% of US stocks
Higher than 41% of US stocks
Higher than 53% of US stocks
Higher than 51% of US stocks
Higher than 72% of US stocks
Higher than 68% of US stocks
Higher than 80% of US stocks
Higher than 77% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GE Healthcare Technologies, Inc. has a market value of $31.3B and an enterprise value of $39.8B.
Revenue in the twelve months to 30 June 2026: $21.3B. The latest quarter grew 5.8% year on year.
Net income over the same four quarters: $2.0B, a 9.6% net margin.
Diluted earnings per share, trailing twelve months: $4.36.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
GE Healthcare Technologies, Inc. spent $400.0M on share buybacks and $64.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 15.8×; forward P/E: 12.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.23%, paying out 3% of earnings.
GE Healthcare Technologies, Inc. employs 54,000 people — $394K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GE Healthcare Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
GE HealthCare said it will report third-quarter 2026 financial results before the market opens on October 28, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time that day.
Why it matters — GEHC watchers can note the date and time when the company plans to share quarterly results and discuss them with investors.
GE HealthCare agreed to a $945 million deal for SOFIE Biosciences, expanding its U.S. PET radiopharmaceutical footprint.
Why it matters — The deal increases GEHC’s exposure to precision care growth, including PET radiopharmaceuticals.
GE HealthCare announced it will acquire privately held Sofie Biosciences for $945 million in cash. The deal is intended to strengthen GE HealthCare's ability to manufacture and distribute PET imaging drugs.
Why it matters — The acquisition expands GE HealthCare's radiopharmaceutical capabilities, adding manufacturing and distribution of PET imaging drugs to its portfolio.
Law Offices of Howard G. Smith announced a securities fraud investigation into GE HealthCare Technologies Inc. and is contacting shareholders who lost money regarding the matter.
Why it matters — A securities fraud investigation into GEHC could signal potential legal and regulatory exposure for the company, which shareholders may want to monitor.
GE HealthCare Technologies has agreed to acquire radiopharmaceutical company Sofie Biosciences for $945 million, a move aimed at expanding into the fast-growing therapeutic radiopharmaceutical market.
Why it matters — The acquisition signals GE HealthCare's strategic push into a high-growth therapeutic area, potentially broadening its portfolio beyond traditional diagnostic imaging.
The 21 Wall Street analysts covering GE Healthcare Technologies, Inc. have a median 12-month price target of $84, with estimates ranging from $70 to $96. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering GE Healthcare Technologies, Inc., 16 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GE Healthcare Technologies, Inc. 68 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, GE Healthcare Technologies, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies +22.7% from the last close, and Ticker Nerd's factor model ranks GE Healthcare Technologies, Inc. 68 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GE Healthcare Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GEHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $96 over the next 12 months.
GE Healthcare Technologies, Inc. returned -5.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products.
The most recent item we track (Business Wire, 7 Oct 2026): "GE HealthCare to announce third quarter 2026 results on October 28, 2026". GE HealthCare said it will report third-quarter 2026 financial results before the market opens on October 28, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time that day.
GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products. Its portfolio supports hospitals, health systems, and clinical providers with tools used in diagnosis, treatment, and patient care across routine and complex medical settings. GE HealthCare also offers software, digital workflows, and service capabilities that help healthcare organizations manage equipment, improve clinical efficiency, and integrate data across care environments. The company’s main business areas include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting its broad role in modern healthcare infrastructure. Headquartered in Chicago, Illinois, GE HealthCare focuses on technologies and services that are widely used in medical imaging, bedside monitoring, and diagnostic procedures worldwide.
CEO Mr. Peter J. Arduini · 54,000 employees · United States · https://www.gehealthcare.com
